Loading...
•
Jun 30, 2023
Maxcyte Q2 2023 Earnings Report
Maxcyte's revenue decreased due to evolving funding environment and prioritization of internal pipeline assets, impacting research and early clinical development projects.
Key Takeaways
Maxcyte reported a 6% decrease in total revenue for Q2 2023, amounting to $9.0 million compared to $9.6 million in Q2 2022. Core business revenue also declined by 14% to $8.3 million. The company signed five SPL partnerships year-to-date, bringing the total to 23. MaxCyte now expects core revenue for 2023 to be comparable to 2022 and SPL program-related revenue expectations remain unchanged at approximately $6 million for the year.
Total revenue decreased by 6% to $9.0 million compared to Q2 2022.
Core business revenue declined by 14% to $8.3 million compared to Q2 2022.
Five SPL partnerships were signed year-to-date, bringing the total to 23.
Core revenue for 2023 is expected to be comparable to 2022, with SPL program-related revenue expected at approximately $6 million.
Revenue by Segment
Forward Guidance
Core revenue for 2023 is expected to be comparable to 2022 and Strategic Platform License (“SPL”) program-related revenue expectations remain unchanged at approximately $6 million for the year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...